Lviv clinical bulletin 2017, 4(20): 25-29

https://doi.org/10.25040/lkv2017.04.025

The Influence of Pathogenetic Treatment on Peroxidation in Patients with Ischemic Heart Disease and Comorbid Nonalcoholic Steatohepatitis

Posted onAuthorAdminЗалишити коментар / Leave a comment

I. Skrypnyk, G. Maslova, O. Shcherbak

HSEE of Ukraine “Ukrainian Medical Stomatological Academy”

Introduction. An excessive activation of lipid peroxidation (LP) plays a significant role in pathogenesis of either ischemic heart disease (IHD) or nonalcoholic steatohepatitis (NASH) that in chronic conditions leads to depletion of antioxidant protection (AOP) enzymes with increased risk of cell damage resulted from the influence of aggressive free radicals.

Aim. To investigate the dynamics of lipid peroxidation and antioxidant protection activity in patients with ischemic heart disease and comorbid nonalcoholic steatohepatitis under the pathogenetic treatment.

Materials and methods. 59 patients with IHD associated with NASH were examined, 11 (18.6 %) of them were women and 48 (81.4 %) – men. An average age was 53.7 ± 8.5 years. An efficiency of treatment was assessed in 1-month and 6-month periods. Activity of alanine (ALT) and aspartate (AST) transaminases, alkaline phosphatase (AP), gamma-glutamyltranspeptidase (GGTP) and total bilirubin content were analyzed in blood serum. Serum thiobarbituric acid-active (TBA-active) products, activity of superoxidedysmutase (SOD) were evaluated. Depending on prescribed therapeutic scheme patients were divided on groups:

І (n = 31) – rosuvastatin 20.0 mg per day, ursodeoxycholic acid (UDCA) 15.0 mg/kg/day for 6 months, and L-carnitine 1.0 g bid for 3 months;

ІІ (n = 28) – rosuvastatin 20.0 mg per day and UDCA 15.0 mg/kg/day, 6 months.

Results. 1 month after the treatment with rosuvastatin 20.0 mg per day in combination with UDCA and L-carnitine in patients of the group І ALT activity decreased 1.8 fold, AST – 2 fold, GGTP – 2.8 fold in comparison with the indexes before the treatment. Among the patients of the group ІІ, who received treatment with rosuvastatin 20.0 mg per day in combination with UDCA, serum ALT decreased 1.5 fold, GGTP – 1.8 fold. In 6-month period serum ALT activity decreased 2.3 fold, AST – 2.4 fold, GGTP – 2.9 fold in patients of the group І in comparison with the indexes before the treatment. GGTP, AP and bilirubin levels were normal. In patients of the group ІІ ALT activity decreased 1.7 fold, AST – 2 fold, GGTP – 2.2 fold in comparison with the indexes before the treatment.

In patients of the group I in 1-month and 6-month periods of treatment serum TBA-reactants decreased 1.9 fold and 2.8 fold respectively with simultaneous SOD activity rise 1.9 and 2.2 fold respectively in comparison with primary evaluation. In patients of the group II in 1-month treatment period content of TBA-reactants decreased 1.7 fold and in 6-month period – 2.9 fold in comparison with the indexes before the treatment. Yet, SOD activity increased 1.9 fold only in 6 months after the treatment.

Conclusion. Combination of ischemic heart disease and nonalcoholic steatohepatitis is accompanied by thiobarbituric acid reactants 3-fold increase and superoxide dismutase 2.3-fold decrease in blood serum in comparison with norms on the background of elevated transaminases. Additional prescription of ursodexoycholic acid and L-carnitine combination for 6 months on the background of pathogenetic therapy allows to decrease thiobarbituric acid reactants 2.8 fold and to increase superoxide dismutase  – 2.2 fold.

References

  1. Anikeevа DO. Indicators of antyoxidant system at the patients with postinfarction cardiosclerosis combined with nonalcoholic steatohepatitis in dynamics of the standard treatment. Ukrainian Medical Almanac. 2012;4:27-29.
  2. Vizir VA, Berezin AE. Immunopathology of atherosclerosis. The value of biological markers for cardiovasclar risk assessment. Ukrainian Medical Journal. 2010;2(76):76-83.
  3. Dolzhenko MM, Bazylevich AYa, Nosenko NM. Influence of non-alcoholic fatty liver disease on course of ischemic heart disease during two-years observation. Ukrainian Cardiology Journal. 2011;2:67-70.
  4. Zhuravleva LV, Krivonosova EM. Comparative characteristics of hepatoprotective drugs. Modern Gastroenterology. 2013;4(72):35-41.
  5. Zvyagintseva TD, Glushchenko SV. Lipotoxic stress and proinflammatory cytokines as factors in the development of nonalcoholic steatohepatitis. Pharmacy. 2014;18(189):46-49.
  6. Kaydashev IP. Methods of clinical and experimental studies in medicine. Poltava: Polimet, 2003. P. 96–99.
  7. Ragino YI, Chernjavski AM, Polonskaya YV, Volkov AM, Kashtanova EV, Tikhonov AV et al. Oxidation and endothelial dysfunction biomarkers of the vascular wall and blood. Bulletin of Experimental Biology and Medicine. 2012;3:308-312.
  8. Svintzitzkiy AS, Solovyova GA, Kvanchuk KL, Dolgaya NE. Non alcoholic steatohepatitis: the treatment with account of pathophysiology. Modern Gastroenterology. 2008;4(42):38-43.
  9. Stalnaia ID, Garishvili TG. A method for malondialdehyde determination with the use of thiobarbituric acid. Modern methods in biochemistry. M.: Medicine, 1977. P. 66-68.
  10. Fadieienko GD, Chernyshov VA. Comorbid pathology influenced on cardiovascular risk in patients survived myocardial infarction. Ukrainian Therapeutical Journal. 2014;2:10-20.
  11. Kharchenko NV, Anokhina GA, Kharchenko VV, Opanasiuk ND, Lopukh IYa. Pathogenetic substantiation of the use of Hepadif in patients with non alcoholic steatohepatitis. Modern Gastroenterology. 2011;6(62):66-71.
  12. Shcherbak OV, Maslova GS. The optimisation of treatment of patients with ischemic heart disease and concomitant nonalcoholic steatohepatitis. Modern Gastroenterology. 2016;5(91):76-83.
  13. Shcherbak ОV, Maslova GS, Skrypnyk IM. Peculiarities of the atherogenic dyslipidemia pathogenesis in patients with ischemic heart disease combined with nonalcoholic steatohepatitis. Bulletin of problems in biology and medicine. 2017;2:199-203.
  14. Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapу (MERCURY) II. Am Heart J. 2006;151(5):975. https://doi.org/10.1016/j.ahj.2005.12.013
  15. Cabezas GR. Efecto del acido ursodesoxicolico combinado con estatinas para el tratamiento de la hipercolesterolemia: ensayo clinico prospective. Rev Clin Esp. 2004;1:632-635.
  16. Di Nicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88:544-551. https://doi.org/10.1016/j.mayocp.2013.02.007